结节病相关肺动脉高压的管理与长期结局
该研究基于法国肺动脉高压注册中心2004至2015年数据,分析126例重度结节病相关肺动脉高压患者。77%接受PAH靶向治疗,4个月后肺血管阻力显著下降但运动能力无改善;中位随访28个月,1、3、5年生存率分别为93%、74%、55%,预后仍差。
要点
- PAH靶向治疗可改善重度S-APH短期肺血流动力学但未提升运动能力
- 部分患者免疫抑制治疗可改善血流动力学
- S-APH长期预后仍较差,5年生存率55%
核心结论
- PAH靶向治疗改善重度S-APH短期肺血流动力学但未改变运动能力,整体预后仍差。
研究设计与样本
- 回顾性队列研究,数据来自法国肺动脉高压注册中心2004至2015年新诊断重度S-APH患者,共126例。
主要发现
- 97例(77%)接受PAH靶向治疗,33例在诊断时启动或升级免疫抑制治疗。
- PAH靶向治疗4个月后肺血管阻力从9.7±4.4降至6.9±3.0 Wood单位(p<0.001),运动能力无显著改善。
- 11例仅接受免疫抑制治疗者中4例血流动力学改善,其中2例有压迫性淋巴结。
- 中位随访28个月,39例需升级PAH靶向治疗,9例接受肺移植,42例死亡。
- 1、3、5年生存率分别为93%、74%、55%。
关键数值与推荐
- 重度S-APH定义:mPAP>35 mmHg,或mPAP 25-35 mmHg且心脏指数<2.5 L·min-1·m-2。
- 患者平均年龄57.5±11.6岁,74%为影像学IV期。
临床怎么用
- 对重度S-APH可考虑PAH靶向治疗以改善短期血流动力学。
- 部分患者可从免疫抑制治疗中获益,尤其存在压迫性淋巴结者。
- 需认识S-APH长期预后差,应密切随访并评估升级治疗或移植。
局限性
- 注册中心回顾性数据,非随机对照设计。
- 仅接受免疫抑制治疗者样本量小(11例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary hypertension (S-APH) are limited.Clinical and haemodynamic data from newly diagnosed patients with severe S-APH (mean pulmonary artery pressure (mPAP) >35 mmHg or mPAP 25-35 mmHg with cardiac index <2.5 L·min-1·m-2) were collected from the French Pulmonary Hypertension Registry between 2004 and 2015.Data from 126 patients with severe S-APH were analysed (mean±sd age 57.5±11.6 years, 74% radiological stage IV). 97 patients (77%) received PAH-targeted therapy and immunosuppressive therapy was initiated or escalated in 33 patients at the time of pulmonary hypertension diagnosis. Four months after PAH-targeted therapy initiation, mean±sd pulmonary vascular resistance decreased from 9.7±4.4 to 6.9±3.0 Wood units (p<0.001), without significant improvement in exercise capacity. Among the 11 patients treated only with immunosuppressive therapy, a haemodynamic improvement was observed in four patients, including two with compressive lymph nodes. After a median follow-up of 28 months, 39 patients needed PAH-targeted therapy escalation, nine underwent lung transplantation and 42 had died. Survival at 1, 3 and 5 years was 93%, 74% and 55%, respectively.PAH-targeted therapy improved short-term pulmonary haemodynamics in severe S-APH without change in exercise capacity. Immunosuppressive therapy improved haemodynamics in selected patients. Pulmonary hypertension in sarcoidosis remains associated with a poor prognosis.
引用
- Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017. PMID: 29051269. doi:10.1183/13993003.00465-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。